Multidisciplinary consensus on the combined management of AlzheimerÓ?s disease by Mexican experts: recommendations and guidelines

Objective: Alzheimer's disease (AD), affecting over 55 million people globally, poses a substantial public health challenge.Early diagnosis and appropriate treatment are vital to slowing its progression and enhancing patient quality of life.The fixed-dose combination of citicoline with rivastigmine emerges as a promising strategy AD treatment.Methods: A real-time Delphi consensus was reached with the participation of 11 Mexican experts.Results: The combination offers neuroprotective benefits, enhancing neuronal regeneration and reducing glutamate levels linked to neuronal damage in AD.These effects translate into improved cognitive function and delayed cognitive decline in AD.Conclusions: The Mexican Consensus for the Combined Management of AD endorses this fixed-dose combination of rivastigmine with citicoline as a new therapeutic perspective.Its efficacy and safety make it a valuable option for the treatment of this neurodegenerative disease.